Cancer Stem Cell Differentiation Compounds Against Tumor Recurrence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments do not effectively target cancer stem cells, leading to tumor recurrence and metastasis, as they focus on de-bulking tumors without addressing the root cause of cancer spread and resistance.
Innovation Solution
Development of compounds that target the embryonic properties of cancer stem cells, inhibiting signaling pathways required for metastasis, thereby forcing differentiation and disrupting cancer stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Volume of moving object
If current cancer treatments (chemotherapy, targeted therapy, immunotherapy) focus on de-bulking tumors, then tumor size is reduced, but cancer stem cells remain untreated leading to tumor recurrence and metastasis
Solution Approach 1:
The patent segments the tumor population into two distinct targets: bulk tumor cells and cancer stem cells. Conventional therapies only address the bulk tumor cells, while this invention introduces compounds that specifically target cancer stem cells through differentiation induction, thereby eliminating the source of recurrence and metastasis while maintaining tumor debulking effects
Solution Approach 2:
The patent changes the therapeutic parameter from单纯 cytotoxic killing to differentiation induction. The compounds alter the state of cancer stem cells by forcing them to differentiate into mature cells, changing their biological properties and eliminating their stemness characteristics, which prevents tumor recurrence and metastasis
2Ease of operation
If cancer stem cells are not targeted, then treatment is simpler and less toxic, but cancer spread and resistance develop
Solution Approach 1:
The patent uses differentiation-inducing compounds as intermediaries to target cancer stem cells. These compounds act as mediators that convert cancer stem cells from a undifferentiated, aggressive state to a differentiated, benign state, thereby preventing cancer spread and resistance without requiring complex combination therapies
Solution Approach 2:
The patent changes the biological parameter of cancer stem cells by inducing differentiation. This parameter change transforms the harmful properties of cancer stem cells (self-renewal, metastasis, resistance) into benign properties (maturation, loss of stemness), thereby preventing cancer spread and resistance
3Reliability
If embryonic properties of cancer stem cells are targeted, then differentiation is forced and metastasis pathways are inhibited, but treatment complexity increases
Solution Approach 1:
The patent changes the biological parameter of cancer stem cells by inducing differentiation through small molecule compounds. This parameter change forces cancer stem cells to exit their undifferentiated state and mature, thereby inhibiting metastasis pathways and improving treatment reliability
Solution Approach 2:
The patent applies the differentiation pathways normally seen in embryonic development to cancer stem cells. By copying these natural embryonic differentiation mechanisms and activating them in cancer stem cells, the treatment achieves metastasis prevention through a biologically familiar process
Data Source
AI summary
Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O′), and (I):